| Title: |
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2) |
| Authors: |
Wiendl, HeinzAff1, IDs40120024006470_cor1; Foley, JohnAff2; Defer, GillesAff3; Zhovtis Ryerson, LanaAff4; Cohen, Jeffrey A.Aff5; Arnold, Douglas L.Aff6; Butzkueven, HelmutAff7; Cutter, Gary R.Aff8; Giovannoni, GavinAff9; Killestein, JoepAff10; Domingo-Horne, RoseAff11; Toukam, MarieAff11; Nunn, AimieAff12; Maghzi, Amir-HadiAff11; Kuhelj, RobertAff13; Lasky, TylerAff11 |
| Source: |
Neurology and Therapy. :1-17 |
| Database: |
Springer Nature Journals |